[go: up one dir, main page]

DK3421470T3 - Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form - Google Patents

Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form Download PDF

Info

Publication number
DK3421470T3
DK3421470T3 DK18178621.1T DK18178621T DK3421470T3 DK 3421470 T3 DK3421470 T3 DK 3421470T3 DK 18178621 T DK18178621 T DK 18178621T DK 3421470 T3 DK3421470 T3 DK 3421470T3
Authority
DK
Denmark
Prior art keywords
crythallic
pyrazolopyridines
fluoro
substituted
crythallic form
Prior art date
Application number
DK18178621.1T
Other languages
English (en)
Inventor
Peter Fey
Alfons Grunenberg
Donald Bierer
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47222101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3421470(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Application granted granted Critical
Publication of DK3421470T3 publication Critical patent/DK3421470T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023—Preparation; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
DK18178621.1T 2011-11-25 2012-11-21 Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form DK3421470T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190789 2011-11-25
EP11192301 2011-12-07
EP12790891.1A EP2782914B1 (de) 2011-11-25 2012-11-21 Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Publications (1)

Publication Number Publication Date
DK3421470T3 true DK3421470T3 (da) 2021-04-06

Family

ID=47222101

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15151593.9T DK2896617T3 (da) 2011-11-25 2012-11-21 Fremgangsmåde til fremstilling af substituerede (z)-alpha-fluoro-beta-amino-acrylaldehyder
DK12790891.1T DK2782914T3 (da) 2011-11-25 2012-11-21 Fremgangsmåde til fremstilling af substituerede 5-fluor-1h-pyrazolopyridiner
DK18178621.1T DK3421470T3 (da) 2011-11-25 2012-11-21 Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK15151593.9T DK2896617T3 (da) 2011-11-25 2012-11-21 Fremgangsmåde til fremstilling af substituerede (z)-alpha-fluoro-beta-amino-acrylaldehyder
DK12790891.1T DK2782914T3 (da) 2011-11-25 2012-11-21 Fremgangsmåde til fremstilling af substituerede 5-fluor-1h-pyrazolopyridiner

Country Status (41)

Country Link
US (7) US8802847B2 (da)
EP (3) EP3421470B8 (da)
JP (4) JP6189315B2 (da)
KR (3) KR101993022B1 (da)
CN (3) CN105503867B (da)
AP (2) AP2014007705A0 (da)
AR (1) AR088983A1 (da)
AU (3) AU2012342547C1 (da)
BR (2) BR112014012414B1 (da)
CA (2) CA3040720C (da)
CL (2) CL2014001339A1 (da)
CO (1) CO6960555A2 (da)
CR (3) CR20210072A (da)
CU (3) CU24354B1 (da)
CY (1) CY1124000T1 (da)
DK (3) DK2896617T3 (da)
DO (3) DOP2014000112A (da)
EA (4) EA030018B1 (da)
EC (1) ECSP14001627A (da)
ES (3) ES2864009T3 (da)
GT (1) GT201400101A (da)
HR (3) HRP20181818T1 (da)
HU (3) HUE031029T2 (da)
IL (3) IL232585A0 (da)
JO (3) JOP20120351B1 (da)
LT (3) LT2782914T (da)
MX (2) MX357481B (da)
MY (3) MY168412A (da)
PE (3) PE20190180A1 (da)
PH (2) PH12014501160B1 (da)
PL (3) PL3421470T3 (da)
PT (3) PT2782914T (da)
RS (3) RS61609B1 (da)
SG (3) SG11201402111QA (da)
SI (3) SI3421470T1 (da)
TR (1) TR201816203T4 (da)
TW (5) TWI631123B (da)
UA (3) UA120278C2 (da)
UY (2) UY34467A (da)
WO (1) WO2013076168A1 (da)
ZA (2) ZA201403613B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
PE20190180A1 (es) 2011-11-25 2019-02-01 Adverio Pharma Gmbh Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
WO2014128109A1 (en) 2013-02-21 2014-08-28 Bayer Pharma Aktiengesellschaft Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
CA3056501A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
JP7542518B2 (ja) 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
CN113272286B (zh) * 2019-01-22 2024-04-16 阿德弗里奥药品有限责任公司 制备4-(2,2,3,3-四氟丙基)吗啉的方法
US20230067593A1 (en) * 2020-02-03 2023-03-02 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3 -yl]pyrimidin-5-yl} carbamate
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP4396185A1 (en) 2021-08-31 2024-07-10 Teva Pharmaceuticals International GmbH Solid state forms of vericiguat and process for preparation thereof
ES2956054B2 (es) 2022-05-03 2024-07-01 Moehs Iberica Sl 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT
CN115043835B (zh) * 2022-06-17 2023-05-09 常州制药厂有限公司 一种维立西呱的精制纯化方法
WO2024038398A1 (en) * 2022-08-18 2024-02-22 Torrent Pharmaceuticals Limited Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat
US20250205235A1 (en) 2023-12-20 2025-06-26 Adverio Pharma Gmbh Dose regimen for vericiguat
CN117924280B (zh) * 2024-03-20 2024-07-12 中国人民解放军军事科学院军事医学研究院 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8606936D0 (en) * 1986-03-20 1986-04-23 Ici Plc Organic compounds
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
JP4351298B2 (ja) 1996-10-14 2009-10-28 バイエル・アクチエンゲゼルシヤフト 新規へテロシクリルメチル置換ピラゾール誘導体
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
BR9915370A (pt) * 1998-11-16 2001-08-14 Basf Ag Composto, uso do mesmo, composição herbicida, processo para preparar composições herbicidas, método para controlar vegetação indesejável, ariluréia, arilanilida, feniluracila trissubstituìda, feniluracila tetrassubstituìda, e, processo para preparar um composto
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
CA2429308C (en) 2000-11-22 2010-09-21 Bayer Aktiengesellschaft Novel lactam-substituted pyrazolopyridine derivatives
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10131987A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Pyridin-substituierte Pyrazolopyridinderivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10351903A1 (de) 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006031175A1 (de) 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
EP2170884A2 (en) 2007-06-25 2010-04-07 Boehringer Ingelheim International GmbH Chemical compounds
JP5553751B2 (ja) 2007-07-31 2014-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド ５−フルオロ−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−アミンおよびその誘導体を調製するためのプロセス
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
KR100979460B1 (ko) * 2008-05-13 2010-09-02 한국과학기술연구원 함불소알킬그룹이 치환된 이온성 액체의 직접 제조방법
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33040A (es) * 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010040233A1 (de) * 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
WO2013030288A1 (de) 2011-09-02 2013-03-07 Bayer Intellectual Property Gmbh Substituierte annellierte pyrimidine und ihre verwendung
PE20190180A1 (es) * 2011-11-25 2019-02-01 Adverio Pharma Gmbh Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas

Also Published As

Publication number Publication date
EA031602B1 (ru) 2019-01-31
EA201690520A1 (ru) 2016-07-29
CN104159898B (zh) 2017-01-18
RS55387B1 (sr) 2017-03-31
KR102026059B1 (ko) 2019-09-26
AP2015008243A0 (en) 2015-01-31
ES2864009T3 (es) 2021-10-13
IL246265B (en) 2018-12-31
EA201892050A1 (ru) 2019-02-28
GT201400101A (es) 2014-11-13
AU2019202123A1 (en) 2019-04-18
HK1223613A1 (zh) 2017-08-04
AU2012342547A1 (en) 2014-06-05
IL263389B (en) 2022-03-01
US20180065942A1 (en) 2018-03-08
UA120278C2 (uk) 2019-11-11
CR20140237A (es) 2014-06-19
SG10201604192XA (en) 2016-07-28
PE20190180A1 (es) 2019-02-01
DK2782914T3 (da) 2018-11-26
CN105503867B (zh) 2019-01-11
EP2782914B1 (de) 2018-08-01
RS61609B1 (sr) 2021-04-29
CN106905314A (zh) 2017-06-30
CU24257B1 (es) 2017-05-10
MY197904A (en) 2023-07-24
US20160009671A1 (en) 2016-01-14
SG11201402111QA (en) 2014-08-28
US9604948B2 (en) 2017-03-28
DOP2014000112A (es) 2014-07-15
CR20210072A (es) 2021-03-22
EA201690521A1 (ru) 2016-06-30
DOP2017000013A (es) 2017-02-15
SG10201604196VA (en) 2016-07-28
PH12014501160A1 (en) 2014-10-20
KR20190018021A (ko) 2019-02-20
CN105503867A (zh) 2016-04-20
PH12014501160B1 (en) 2014-10-20
JP6392436B2 (ja) 2018-09-19
US10364229B2 (en) 2019-07-30
AU2019202123B2 (en) 2020-09-24
HRP20161501T1 (hr) 2016-12-16
LT2782914T (lt) 2018-10-10
MX375872B (es) 2025-03-07
US9150573B2 (en) 2015-10-06
CO6960555A2 (es) 2014-05-30
LT3421470T (lt) 2021-04-26
KR101943788B1 (ko) 2019-01-29
US20190177288A1 (en) 2019-06-13
BR112014012414A8 (pt) 2018-01-23
JP2018199698A (ja) 2018-12-20
NZ721592A (en) 2018-02-23
PT2782914T (pt) 2018-11-16
AP2014007705A0 (en) 2014-06-30
KR20170130612A (ko) 2017-11-28
BR112014012414A2 (pt) 2017-06-06
CL2014001339A1 (es) 2014-10-17
EP3421470A1 (de) 2019-01-02
EA033455B1 (ru) 2019-10-31
SI2896617T1 (sl) 2016-12-30
JOP20210065A1 (ar) 2023-01-30
DK2896617T3 (da) 2016-12-12
UA116623C2 (uk) 2018-04-25
CA3040720C (en) 2021-06-15
TWI597280B (zh) 2017-09-01
HRP20210507T1 (hr) 2021-05-28
AP3898A (en) 2016-11-16
US20170158652A1 (en) 2017-06-08
PL2782914T3 (pl) 2019-01-31
JP6189315B2 (ja) 2017-08-30
JOP20210064A1 (ar) 2023-01-30
CY1124000T1 (el) 2022-05-27
PT3421470T (pt) 2021-03-31
NZ724215A (en) 2018-03-23
US10633356B2 (en) 2020-04-28
CA2856706A1 (en) 2013-05-30
HUE041592T2 (hu) 2019-05-28
UY34467A (es) 2013-06-28
US20140315926A1 (en) 2014-10-23
IL263389A (en) 2018-12-31
SI2782914T1 (sl) 2018-12-31
CL2016000344A1 (es) 2017-02-10
EA030018B1 (ru) 2018-06-29
EP2896617A1 (de) 2015-07-22
ZA201505970B (en) 2017-08-30
EA201491028A8 (ru) 2016-01-29
JOP20120351B1 (ar) 2021-08-17
JP2018058860A (ja) 2018-04-12
TWI665198B (zh) 2019-07-11
AR088983A1 (es) 2014-07-23
KR20140105483A (ko) 2014-09-01
PE20142359A1 (es) 2015-01-09
HRP20181818T1 (hr) 2019-01-11
TWI631123B (zh) 2018-08-01
KR101993022B1 (ko) 2019-06-25
SI3421470T1 (sl) 2021-07-30
UA119269C2 (uk) 2019-05-27
MX2014006018A (es) 2014-06-04
JP6340391B2 (ja) 2018-06-06
WO2013076168A1 (de) 2013-05-30
CU20150124A7 (es) 2016-03-31
ES2603028T8 (es) 2021-12-29
TW201838993A (zh) 2018-11-01
JP2015502932A (ja) 2015-01-29
ZA201403613B (en) 2016-02-24
PH12015501494A1 (en) 2015-09-07
CA2856706C (en) 2020-06-16
EA201491028A1 (ru) 2014-12-30
ES2603028T3 (es) 2017-02-23
HUE031029T2 (en) 2017-06-28
EP2896617B1 (de) 2016-10-05
AU2012342547B2 (en) 2017-08-17
US20190177287A1 (en) 2019-06-13
US9845300B2 (en) 2017-12-19
TW201329076A (zh) 2013-07-16
AU2017254916A1 (en) 2017-11-23
CU24354B1 (es) 2018-08-06
NZ624593A (en) 2016-10-28
HK1203951A1 (en) 2015-11-06
US8802847B2 (en) 2014-08-12
RS57945B1 (sr) 2019-01-31
IL246265A0 (en) 2016-07-31
ES2694158T3 (es) 2018-12-18
MY168412A (en) 2018-11-09
PH12015501494B1 (en) 2015-09-07
IL232585A0 (en) 2014-06-30
DOP2021000179A (es) 2021-09-30
CA3040720A1 (en) 2013-05-30
PL2896617T3 (pl) 2017-07-31
CN104159898A (zh) 2014-11-19
TW201708219A (zh) 2017-03-01
TW201831447A (zh) 2018-09-01
PT2896617T (pt) 2016-11-18
MY198086A (en) 2023-07-31
US20130143900A1 (en) 2013-06-06
TWI659016B (zh) 2019-05-11
BR122020001312B1 (pt) 2022-02-15
PL3421470T3 (pl) 2021-08-02
CR20190057A (es) 2019-04-23
CU20150123A7 (es) 2016-03-31
ECSP14001627A (es) 2015-11-30
JP2017031180A (ja) 2017-02-09
TW201932465A (zh) 2019-08-16
AU2017254916B2 (en) 2019-02-28
PE20190181A1 (es) 2019-02-01
LT2896617T (lt) 2016-12-12
MX357481B (es) 2018-07-11
UY39646A (es) 2022-04-29
CU20140055A7 (es) 2014-10-02
AU2012342547C1 (en) 2019-02-21
EP3421470B8 (de) 2021-08-11
EP2782914A1 (de) 2014-10-01
US10633357B2 (en) 2020-04-28
BR112014012414B1 (pt) 2022-01-11
HUE053745T2 (hu) 2021-07-28
EP3421470B1 (de) 2021-01-20
TR201816203T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2780065A4 (en) NASAL MASK SYSTEM
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
EP2752374A4 (en) gooseneck
IL231616A0 (en) Tropicalizing agent
EP2795884A4 (en) Audio conferencing
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
EP2701512A4 (en) Aldosterone synthase inhibitors
EP2768739A4 (en) EYEWASH FLUID CONTAINER
EP2786752A4 (en) Ropinirole-containing adhesive patch
EP2723481A4 (en) FLOW COMPENSATOR
DK3141251T3 (da) Koloskopi - forberedelse
EP2708561A4 (en) BIO-PIN
EP2762923A4 (en) RADIATION MEASURING DEVICE
EP2738148A4 (en) RECIPROCAL LOCKING BLOCK
DE112011104936A5 (de) Stanzstauchniet
EP2760803A4 (en) Geopolymer product
EP2771685A4 (en) BIOMARKERS OF CANCER
DE112012000958A5 (de) Handsäge
EP2788163A4 (en) POST-MOLDING SYSTEM
EP2729467A4 (en) CRYPTATE COMPOUNDS